IL6 and familial hypercholesterolemia: The efficacy of FAR against liver injury was accompanied with decreased LPO, IL-1β, IL-6, and TNF-α, and enhanced antioxidants in experimental hypercholesterolemia (Abukhalil et al., 2020[3]) and APAP hepatotoxicity (Gayatri Devi and Ezhilarasan, 2023[19]).